| 摘要 |
The present invention relates to novel GPR 119 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.; |
| 主权项 |
1. A compound of formula (I), its tautomeric form, its stereoisomer, and pharmaceutically acceptable salt thereof wherein R1 represents H or an optionally substituted group selected from a member of the group consisting of linear or branched (C1-C6)-alkyl, haloalkyl, (C1-C6)alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, alkylsulfonyl, and arylsulfonyl groups, or a group represented by (CH2)mCO2R4, (CH2)mCOR4 or (CH2)mCONH2 wherein each R4 independently represents H or a group selected from a member of the group consisting of linear or branched (C1-C6)alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl; and m is an integer of 0 to 3; R2 represents H, cyano, nitro, formyl, linear or branched (C1-C6) alkyl, or (C1-C6) alkoxyl; R3 represents an optionally substituted group selected from a member of the group consisting of linear or branched (C1-C6)alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroaralkyl or a group represented by C(O)OR5, C(O)R5, and SO2R5 wherein each R5 independently represents H or an optionally substituted group selected from a member of the group consisting of linear or branched (C1-C6)alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hererocyclylalkyl, heteroaryl, and heteroaralkyl groups; n represents an integer from 0 to 3; and “A” represents wherein p represents an integer from 1 to 3; and X represents O or S. |
